

### National Heart, Lung, and Blood Institute; Notice of a Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Heart, Lung, and Blood Special Emphasis Panel (SEP) meeting:

*Name of SEP:* Refinement on Clinical Use of New Assays for Direct Detection of Viral Nucleic Acids in Donated Blood, Organs and Tissues (Teleconference Call).

*Date:* June 15, 1995.

*Time:* 11:00 a.m.

*Place:* 6701 Rockledge Drive, Room 7178, Bethesda, Maryland.

*Contact Person:* David M. Monsees, Jr., Ph.D., 6701 Rockledge Drive, Room 7178, Bethesda, Maryland 20892-7294, (301) 435-0270.

*Purpose/Agenda:* To review and evaluate contract proposals.

The meeting will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5 U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than fifteen days prior to the meeting due to the urgent need to meet timing limitations imposed by the grant review cycle.

(Catalog of Federal Domestic Assistance Programs Nos. 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; and 93.839, Blood Diseases and Resources Research, National Institutes of Health.)

Dated: May 30, 1995.

**Susan K. Feldman,**

*Committee Management Officer, NIH.*

[FR Doc. 95-13713 Filed 6-5-95; 8:45 am]

BILLING CODE 4140-01-M

### National Institute of Dental Research; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Institute of Dental Research Special Emphasis Panel (SEP) meetings:

*Name of SEP:* National Institute of Dental Research Special Emphasis Panel—Trigeminal Pain Mechanisms & Control Center.

*Dates:* June 14-15, 1995.

*Time:* 8:00 a.m.

*Place:* Hyatt Hotel Dulles, 2300 Dulles Corner Boulevard, Herndon, VA.

*Contact Person:* Dr. Yong Shin, Scientific Review Administrator, 4500 Center Drive, Natcher Building, Room 4AN-38J, Bethesda, MD 20892, (301) 594-2372.

*Purpose/Agenda:* To evaluate and review grant applications and/or contract proposals.

*Name of SEP:* National Institute of Dental Research Special Emphasis Panel—Advanced Dental Restorative Systems Program Project.

*Date:* July 18, 1995.

*Time:* 8:00 a.m.

*Place:* National Institutes of Health, 4500 Center Drive, Natcher Building, Conf. Room A, Bethesda, MD 20892.

*Contact Person:* Dr. Yong Shin, Scientific Review Administrator, 4500 Center Drive, Natcher Building, Room 4AN-38J, Bethesda, MD 20892, (301) 594-2372.

*Purpose/Agenda:* To evaluate and review grant applications and/or contract proposals.

*Name of SEP:* National Institute of Dental Research Special Emphasis Panel—Dentin Characterization Program Project.

*Date:* July 19, 1995.

*Time:* 8:00 a.m.

*Place:* National Institutes of Health, 4500 Center Drive, Natcher Building, Conf. Room A, Bethesda, MD 20892.

*Contact Person:* Dr. Yong Shin, Scientific Review Administrator, 4500 Center Drive, Natcher Building, Room 4AN-38J, Bethesda, MD 20892, (301) 594-2372.

*Purpose/Agenda:* To evaluate and review grant applications and/or contract proposals.

*Name of SEP:* National Institute of Dental Research Special Emphasis Panel—Facial Profile SBIR.

*Dates:* August 22, 1995.

*Time:* 8:00 a.m.

*Place:* Wellesley College Club Inn, 44 Commonwealth Avenue, Boston, MA.

*Contact Person:* Dr. George Hausch, Chief, Review Section, 4500 Center Drive, Natcher Building, Room 4AN-38J, Bethesda, MD 20892, (301) 594-2372.

Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program No. 93.121, Oral Diseases and Disorders Research.)

Dated: May 30, 1995.

**Susan K. Feldman,**

*Committee Management Officer, NIH.*

[FR Doc. 95-13714 Filed 6-5-95; 8:45 am]

BILLING CODE 4140-01-M

### Opportunity for a Cooperative Research and Development Agreement (CRADA) and Licensing Opportunity for Testosterone Bucyclate

**AGENCIES:** National Institute of Child Health and Human Development, National Institutes of Health, Public Health Service, DHHS; and UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (WHO/HRP).

**ACTION:** Notice.

**SUMMARY:** The National Institutes of Health and the World Health Organization are seeking (a) partner(s) for the further development, evaluation and commercialization of testosterone bucyclate and pharmaceutical compositions thereof. The invention claimed in the issued U.S. patent referenced below is available for either exclusive or non-exclusive licensing. Licensing by NIH is subject to 35 U.S.C. 207 and 37 CFR part 404.

### Long-Acting Androgenic Compounds and Pharmaceutical Compositions Thereof

**Inventors:** Sydney Archer, Gabriel Bialy, Richard P. Blye, Pierre Crabbe, Egon R. Diczfalussy, Carl Djerassi, Josef Fried and Hyun K. Kim

**Assignees:** National Institutes of Health and the World Health Organization

**Issued:** August 14, 1990

**Patent Number:** 4,948,790

To expedite the research, development and commercialization of testosterone bucyclate, the National Institutes of Health and the World Health Organization are seeking one or more CRADA and/or license agreements with pharmaceutical or biotechnology companies in accordance with the regulations governing the transfer of Government-developed agents and WHO's public sector objectives, as outlined below. Any proposal to use or develop these drugs will be considered.

### SUPPLEMENTARY INFORMATION:

Androgens are principally employed in therapeutic medicine for replacement or supplementation in androgen deficiency states but also find use in hypopituitarism, menstrual disorders, anemia, promotion of anabolism, suppression of lactation and as a palliative measure in recurrent and metastatic carcinoma of the breast. NIH's and WHO's interest is to develop testosterone bucyclate for use as a hormonal method of male contraception and for androgen replacement in other methods of male contraception which usually compromise the endocrine as well as the gametogenic function of the testis. Long-term androgen therapy is complicated by the side effects and/or poor bioavailability of oral preparations and the need for frequent injections of parenteral products. Two of the most commonly used injectable androgens, testosterone enanthate and testosterone cypionate, must be administered about every two weeks. There is thus a crucial need for longer-acting injectable androgens.

Testosterone bucyclate emanated, in 1980, from a joint NIH-WHO-sponsored steroid synthesis program in which the